Cabozantinib to Treat Resistant Form of Thyroid Cancer

Radioactive iodine therapy is the standardized treatment for thyroid cancer but nearly 15 percent of these patients have cancers that are resistant to the therapy. Cabozantinib drug could be a new firstline therapy for metastatic, radioactive iodine-resistant thyroid cancer.

Related Links